Laurus Labs gets USFDA inspection report for Achutapuram unit 

The company has received the EIR from the US Food and Drug Administration for its finished dosage formulations and active pharmaceutical ingredients manufacturing plant.

Published: 15th September 2017 06:39 PM  |   Last Updated: 15th September 2017 06:39 PM   |  A+A-

By PTI

NEW DELHI: Drug firm Laurus Labs today said it has received the establishment inspection report (EIR) from the US health regulator after inspection of a unit of the company's Achutapuram facility in Vishakhapatnam.

The company has received the EIR from the US Food and Drug Administration (USFDA) for its finished dosage formulations and active pharmaceutical ingredients manufacturing plant, unit two at Achutapuram, Laurus Labs said in a filing to the BSE.

The inspection of the facility was completed in May 2017, it added.

Shares of Laurus Labs Ltd today closed at Rs 549.80 per scrip on BSE, up 0.04 per cent from its previous close. 

Stay up to date on all the latest Business news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL2018